ナミキ商事株式会社 医薬品及び創薬化学品の専門商社

医薬品及び創薬化学品の専門商社

検索検索

バイオ製品Bio Products

タンパク質、抗体、アッセイキット

タンパク質カタログ

輸入に関する法規制チェックは、御見積のご依頼をいただいた際に行います。
法規制によっては、定価として記載の価格に追加の費用が発生する場合や供給出来ない場合がございますので、あらかじめご了承ください。

サプライヤー
TargteMol
カタログNo.
TMPY-03407
製品名称
NQO1 Protein, Human, Recombinant (His)
タンパク質名
NQO1
Species
Human
HOST
E. coli
50μg: -
お問い合わせ

Overview

Synonyms NAD(P)H dehydrogenase, quinone 1, NMORI, DIA4, QR1, NMOR1, DTD, DHQU
Characteristics Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
Endotoxin Level Please contact us for more information.
Purity SDS-PAGE: 96%; SEC-HPLC: 99.7%
Description NQO1 gene is a member of the NAD(P)H dehydrogenase (quinone) family and encodes a cytoplasmic 2-electron reductase. NQO1 forms homodimers and reduces quinones to hydroquinones. NQO1's enzymatic activity prevents the one-electron reduction of quinones that results in the production of radical species. Mutations in the NQO1 gene have been associated with tardive dyskinesia (TD), an increased risk of hematotoxicity after exposure to benzene, and susceptibility to various forms of cancer. Altered expression of NQO1 has been seen in many tumors and is also associated with Alzheimer's disease (AD). Alternate transcriptional splice variants, encoding different isoforms, have been characterized. Recent pharmacological research suggests the feasibility of genotype-directed redox chemotherapeutic intervention targeting NQO1 breast cancer, a common missense genotype encoding a functionally impaired NQO1 protein.
Reference Adesnik M. et al., 1988, J Biol Chem. 263 (27): 13572-8.,Ross David. et al., 2002, J Biol Chem. 277 (16): 14060-7.,Cabello CM. et al., 2010, Free Radic Res. 45 (3): 276-92.
URL https://www.targetmol.com/recombinant-protein/nqo1_protein_human_recombinant_his_tag_

お問い合わせリスト(-)

お問い合わせフォーム